Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 284-289

  Groenewegen, G ^a   Walraven, M ^a,b   Vermaat, J ^a   De Gast, B ^c   Witteveen, E ^a   Giles, R ^a   Haanen, J ^c   Voest, E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

atrasentan; endothelin axis; IFN ; mRCC; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; ATRASENTAN; BILIRUBIN; CREATININE; ENDOTHELIN 1; GAMMA GLUTAMYLTRANSFERASE; VASCULOTROPIN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER PAIN; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; INSOMNIA; KIDNEY CARCINOMA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALAISE; MALE; MOOD; NAUSEA; NEUROPATHY; NEUTROPENIA; NOSE CONGESTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENDOTHELINS; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLIDINES;

EID: 84856491321     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.515     Document Type: Article

References (30)

1. Medical Research Council Renal Cancer Collaborators (1999) Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14-17
2. Bagnato A, Rosano L (2008) The endothelin axis in cancer. Int J Biochem Cell Biol 40: 1443-1451
3. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175: 859-863 (Pubitemid 43199997)
4. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180 (Pubitemid 34408809)
5. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679-689 (Pubitemid 46621903)
6. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966 (Pubitemid 350036854)
7. Coppin C (2008) Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther 8: 907-919
8. Dirim A, Haberal AN, Goren MR, Tekin MI, Peskircioglu L, Demirhan B, Ozkardes H (2008) VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol 40: 861-868
9. Djordjevic G, Mozetic V, Mozetic DV, Licul V, Ilijas KM, Mustac E, Oguic R, Fuckar Z, Jonjic N (2007) Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 203: 99-106 (Pubitemid 46173164)
10. Douglas ML, Richardson MM, Nicol DL (2004) Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 100: 2118-2124 (Pubitemid 38580329)
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134 (Pubitemid 46089673)
12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111 (Pubitemid 350296300)
13. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611 (Pubitemid 39099316)
14. Gorenflo M, Ullmann MV, Herpel E, Neumayer S, Dieckmann R, Demirakca S, Klimpel H, Hagl S, Gebhard MM (2007) Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow. J Cardiovasc Pharmacol 50: 286-292 (Pubitemid 47428977)
15. Kirkwood J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29: 18-26
16. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296 (Pubitemid 34032623)
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
18. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116 (Pubitemid 37328878)
19. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Geldern TW, Wessale JL, Winn M, Wu-Wong JR (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETAselective receptor antagonist. J Pharmacol Exp Ther 276: 473-481 (Pubitemid 126660483)
20. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, Nelson JB (2007) Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 246: 139-148 (Pubitemid 44959383)
21. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson III WE (2008) VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 28: 553-561
22. Rosano L, Spinella F, Salani D, Di CV, Venuti A, Nicotra MR, Natali PG, Bagnato A (2003) Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63: 2447-2453 (Pubitemid 36605182)
23. Rosewicz S, Detjen K, Scholz A, von MZ (2004) Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80(Suppl 1): 85-93 (Pubitemid 39382376)
24. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Andre AK, Wang Q, Carr RA, Ratain MJ (2004) Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 10: 4406-4411 (Pubitemid 38878881)
25. Spinella F, Rosano L, Di C, V, Natali PG, Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 277: 27850-27855 (Pubitemid 34966730)
26. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA (2000) Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 86: 203-207 (Pubitemid 30621216)
27. Tochizawa S, Masumori N, Yanai Y, Ohmoto Y, Yabuuchi Y, Tsukamoto T (2008) Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Biomed Res 29: 271-278
28. Verheul HM, Hoekman K, Luykx-de BS, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3: 2187-2190 (Pubitemid 28133134)
29. Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, Liu KD (2005) Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 131: 169-178 (Pubitemid 40175011)
30. Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Humerickhouse RA, Isaacson JD, Carr RA, Voest E (2003) Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9: 2965-2972 (Pubitemid 37006310)